Table 1.

General characteristics, Clinical Frailty Scale scores and the serum level of anti-SARS-CoV-2 IgG antibodies in serum in the studied long-term care facility residents before and after vaccination, taking into account SARS-CoV-2 infection

Parameter	Investigated patients
	Pre-vaccine		Post-vaccine First dose		Post-vaccine Second dose		Only first dose regimen
	Uninfected (n = 20)	Previously infected (n = 58)	Uninfected (n = 18)	Previously infected (n = 52)	Uninfected (n = 16)	Previously infected (n = 46)	Uninfected (n = 1)	Previously infected (n = 5)
Age (years; mean ± SD)	85.55 ± 7.16	85.78 ± 7.79	84.61 ± 6.01	85.56 ± 8.01	84.31 ± 6.29	85.09 ± 8.25	85	88.80 ± 5.40
Sex (male/female)	10/10	13/45	9/9	12/40	8/8	11/35	0/1	1/4
sCFS (median/IQR/range)	5/4/1–7	6/2/3–8	5/4/1–7	6/2/3–8	5/3.5/1–7	6/2/3–8	5//5	6/2.2/4–7
Serum level of anti-SARS-CoV-2 IgG (AU/ml) (median/IQR/range)	0.23/0.17/0.10–4.69	73.56/ 168.55/ 10.86–1372.23	4.76/21.59/ 0.24–232.96	433.58/670.40/ 107.02–3956.48	116.50/328.00/ 11.56–1597.56	531.59/433.64/ 133.25–1989.15	0.60	988.15/468.90/ 354.17–1114.69

CFS Clinical Frailty Scale, IQR interquartile range